Work

A Cost-Benefit Analysis of Bivalent Covid-19 Vaccines

Year: 2023

Type: article

Abstract: The cost-benefit ratios of the bivalent vaccines were unknown. To address this issue, we considered surveillance data on the administration of the Moderna and Pfizer-BioNTech bivalent vaccines and clinical outcomes from September 1, 2022 to February 10, 2023 for North Carolina residents 12 years of age or older. We found that booster vaccination was much more beneficial for people 65 years of age or older than for people 12–64 years of age, mainly because the risks of hospitalization and death were much higher in the older age group.

Source: Journal of Biotechnology and Biomedicine

DOI: 10.26502/jbb.2642-91280116

Authors: Dan-Yu Lin, Yangjianchen Xu, Donglin Zeng, Shadia Khan Sunny

Institutions: University of North Carolina at Chapel Hill, NC Department of Health and Human Services

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases